Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$66.6B
sum of reported positions
Reported positions
345
Changes vs prior quarter
330
54 new · 35 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 170 measured positions in 8 quarters, the typical new or larger position finished −2.7 pts against the S&P 500 and 41% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 146M | $24.9B | 37.4% | |
| 12.5M | $5.27B | 7.9% | |
| 3.21M | $1.8B | 2.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $33.1B | $66.6B |
| Positions | 326 | 345 |
| Biggest line | — | Space Exploration Technologies 37% |
| 15.9M |
| $1.54B |
| 2.3% |
| 7.28M | $1.41B | 2.1% |
| 11.2M | $1.27B | 1.9% |
| 2.43M | $1.12B | 1.7% |
| 8.99M | $1.11B | 1.7% |
| 11.7M | $1.08B | 1.6% |
| 16.4M | $1.07B | 1.6% |
| 1.98M | $1.04B | 1.6% |
| 9.33M | $1.03B | 1.5% |
| 7.6M | $985M | 1.5% |
| 4.2M | $967M | 1.5% |
| 6.54M | $890M | 1.3% |
| 2.66M | $879M | 1.3% |
| 4.7M | $844M | 1.3% |
| 14.7M | $634M | 1.0% |
| 60M | $613M | 0.9% |
| 21.6M | $612M | 0.9% |
| 16.9M | $600M | 0.9% |
| 2.97M | $593M | 0.9% |
| 3.5M | $546M | 0.8% |
| 1.96M | $466M | 0.7% |
| 4.81M | $418M | 0.6% |
Brookfield Asset Management (BAM)
398K → 103K shares (−74%)
UnitedHealth (UNH)
10K shares
Palo Alto Networks (PANW)
18K → 11K shares (−40%)
Blackstone Mortgage Trust, Inc. (BXMT)
1.57M → 191K shares (−88%)
Vertex Pharmaceuticals (VRTX)
7,500 → 6,000 shares (−20%)
Elanco (ELAN)
163K → 118K shares (−28%)
Verisign (VRSN)
14K → 11K shares (−21%)
Merck (MRK)
25K → 22K shares (−12%)
Moelis & Company (MC)
163K → 43K shares (−74%)
Natera (NTRA)
17K → 10K shares (−39%)
Guardant Health (GH)
32K → 17K shares (−48%)
Applied Materials (AMAT)
3,392 shares
Madrigal Pharmaceuticals (MDGL)
5,300 → 4,500 shares (−15%)
Revolution Medicines (RVMD)
2,500 → 13K shares (+400%)
Bank of America (BAC)
28K → 41K shares (+45%)
Gilead Sciences (GILD)
30K → 18K shares (−40%)
Wyndham Hotels & Resorts (WH)
26K shares
Bloom Energy (BE)
7,204 shares
Morgan Stanley (MS)
9,100 → 9,620 shares (+6%)
Protagonist Therapeutics, Inc. (PTGX)
15K → 16K shares (+7%)
Elevance Health (ELV)
5,000 shares
Agnico Eagle Mines (AEM)
13K → 12K shares (−9%)
Deutsche Bank Aktiengesellschaft (DB)
140K → 51K shares (−63%)
JPMorgan Chase (JPM)
5,300 shares
Oddity Tech (ODD)
63K → 89K shares (+43%)
